Pfizer Up: PF-3944 Data, BaseLaunch & Guidance Q2.
Pfizer’s recent week brought tangible catalysts: promising PF-3944 obesity data, a BaseLaunch partnership for early-stage access, confirmation of 2026 guidance and an FDA Priority Review for HYMPAVZI. These developments created near-term upside for PFE while setting a clear, pipeline-driven roadmap for 2026.
